Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States

Chronic hepatitis C (CHC) disproportionately affects racial minorities in the United States (US). Although prior studies have reported lower treatment rates in Blacks than in Caucasians, the rates of other minorities remain understudied. We aimed to examine antiviral treatment rates by race and to e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2016-05, Vol.95 (22), p.e3719-e3719
Hauptverfasser: Vutien, Philip, Hoang, Joseph, Brooks, Louis, Nguyen, Nghia H., Nguyen, Mindie H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e3719
container_issue 22
container_start_page e3719
container_title Medicine (Baltimore)
container_volume 95
creator Vutien, Philip
Hoang, Joseph
Brooks, Louis
Nguyen, Nghia H.
Nguyen, Mindie H.
description Chronic hepatitis C (CHC) disproportionately affects racial minorities in the United States (US). Although prior studies have reported lower treatment rates in Blacks than in Caucasians, the rates of other minorities remain understudied. We aimed to examine antiviral treatment rates by race and to evaluate the effect of other demographic, medical, and psychiatric factors on treatment rates. We performed a population-based study of adult CHC patients identified via ICD-9CM query from OptumInsight's Data Mart from January 2009 to December 2013. Antiviral treatment was defined by pharmaceutical claims for interferon and/or pegylated-interferon. A total of 73,665 insured patients were included: 51,282 Caucasians, 10,493 Blacks, 8679 Hispanics, and 3211 Asians. Caucasians had the highest treatment rate (10.7%) followed by Blacks (8.8%), Hispanics (8.8%), and Asians (7.9%, P 
doi_str_mv 10.1097/MD.0000000000003719
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4900706</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1793904804</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3552-5dd77134661b3eb8e306531f9fe7235e3bd3790a65820c714acad0d555045de73</originalsourceid><addsrcrecordid>eNpdkd1u1DAQhS0EotvCEyAhX3JByvg_5gKpZIEitaIq7bXlTRxiyMap7W3Vd-Ch8XZLVfCNrTnfnDPyIPSKwCEBrd6dLg_h0WGK6CdoQQSTldCSP0ULACoqpRXfQ_sp_QQgTFH-HO1RRUXNdb1Av89t6-2Ilz7NNvrsXcJ-whfR2bx2U8bnNpdSHyJuhhgm3-JjN9tcyISb9_hosuNtKu_QY4vPwrwZixim6qNNrsNNGELMW1Gxt1IKfFbUYnsXkgeHLyefC_c9b2NeoGe9HZN7eX8foMvPny6a4-rk25evzdFJ1TIhaCW6TinCuJRkxdyqdgykYKTXvVOUCcdWHVMarBQ1hVYRblvbQSeEAC46p9gB-rDznTertevaMlC0o5mjX9t4a4L15l9l8oP5Ea4N1wAKZDF4c28Qw9XGpWzWPrVuHO3kwiYZojTTwGvgBWU7tI0hpej6hxgCZrtHc7o0_--xdL1-POFDz9_FFYDvgJswZhfTr3Fz46IZnB3zcOcnlKYVBSKh_A1UpUIo-wPx_ag4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1793904804</pqid></control><display><type>article</type><title>Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Vutien, Philip ; Hoang, Joseph ; Brooks, Louis ; Nguyen, Nghia H. ; Nguyen, Mindie H.</creator><creatorcontrib>Vutien, Philip ; Hoang, Joseph ; Brooks, Louis ; Nguyen, Nghia H. ; Nguyen, Mindie H.</creatorcontrib><description>Chronic hepatitis C (CHC) disproportionately affects racial minorities in the United States (US). Although prior studies have reported lower treatment rates in Blacks than in Caucasians, the rates of other minorities remain understudied. We aimed to examine antiviral treatment rates by race and to evaluate the effect of other demographic, medical, and psychiatric factors on treatment rates. We performed a population-based study of adult CHC patients identified via ICD-9CM query from OptumInsight's Data Mart from January 2009 to December 2013. Antiviral treatment was defined by pharmaceutical claims for interferon and/or pegylated-interferon. A total of 73,665 insured patients were included: 51,282 Caucasians, 10,493 Blacks, 8679 Hispanics, and 3211 Asians. Caucasians had the highest treatment rate (10.7%) followed by Blacks (8.8%), Hispanics (8.8%), and Asians (7.9%, P &lt; .001). Hispanics had the highest cirrhosis rates compared with Caucasians, Blacks, and Asians (20.7% vs 18.3%, 17.1%, and 14.3%, respectively). Caucasians were the most likely to have a psychiatric comorbidity (20.1%) and Blacks the most likely to have a medical comorbidity (44%). Asians were the least likely to have a psychiatric (6.4%) or medical comorbidity (26.9%). On multivariate analysis, racial minority was a significant predictor of nontreatment with odds ratios of 0.82 [confidence interval (CI): 0.74-0.90] for Blacks, 0.87 (CI: 0.78-0.96) for Hispanics, and 0.73 (CI: 0.62-0.86) for Asians versus Caucasians. Racial minorities had lower treatment rates than Caucasians. Despite fewer medical and psychiatric comorbidities and higher incomes and educational levels, Asians had the lowest treatment rates. Hispanics also had lower treatment rates than Caucasians despite having higher rates of cirrhosis. Future studies should aim to identify underlying racial-related barriers to hepatitis C virus treatment besides socioeconomic status and medical or psychiatric comorbidities.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000003719</identifier><identifier>PMID: 27258498</identifier><language>eng</language><publisher>United States: The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adult ; Continental Population Groups ; Female ; Hepatitis C, Chronic - ethnology ; Humans ; Male ; Middle Aged ; Morbidity - trends ; Observational Study ; Population Surveillance - methods ; Retrospective Studies ; United States - epidemiology</subject><ispartof>Medicine (Baltimore), 2016-05, Vol.95 (22), p.e3719-e3719</ispartof><rights>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3552-5dd77134661b3eb8e306531f9fe7235e3bd3790a65820c714acad0d555045de73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900706/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900706/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27258498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vutien, Philip</creatorcontrib><creatorcontrib>Hoang, Joseph</creatorcontrib><creatorcontrib>Brooks, Louis</creatorcontrib><creatorcontrib>Nguyen, Nghia H.</creatorcontrib><creatorcontrib>Nguyen, Mindie H.</creatorcontrib><title>Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Chronic hepatitis C (CHC) disproportionately affects racial minorities in the United States (US). Although prior studies have reported lower treatment rates in Blacks than in Caucasians, the rates of other minorities remain understudied. We aimed to examine antiviral treatment rates by race and to evaluate the effect of other demographic, medical, and psychiatric factors on treatment rates. We performed a population-based study of adult CHC patients identified via ICD-9CM query from OptumInsight's Data Mart from January 2009 to December 2013. Antiviral treatment was defined by pharmaceutical claims for interferon and/or pegylated-interferon. A total of 73,665 insured patients were included: 51,282 Caucasians, 10,493 Blacks, 8679 Hispanics, and 3211 Asians. Caucasians had the highest treatment rate (10.7%) followed by Blacks (8.8%), Hispanics (8.8%), and Asians (7.9%, P &lt; .001). Hispanics had the highest cirrhosis rates compared with Caucasians, Blacks, and Asians (20.7% vs 18.3%, 17.1%, and 14.3%, respectively). Caucasians were the most likely to have a psychiatric comorbidity (20.1%) and Blacks the most likely to have a medical comorbidity (44%). Asians were the least likely to have a psychiatric (6.4%) or medical comorbidity (26.9%). On multivariate analysis, racial minority was a significant predictor of nontreatment with odds ratios of 0.82 [confidence interval (CI): 0.74-0.90] for Blacks, 0.87 (CI: 0.78-0.96) for Hispanics, and 0.73 (CI: 0.62-0.86) for Asians versus Caucasians. Racial minorities had lower treatment rates than Caucasians. Despite fewer medical and psychiatric comorbidities and higher incomes and educational levels, Asians had the lowest treatment rates. Hispanics also had lower treatment rates than Caucasians despite having higher rates of cirrhosis. Future studies should aim to identify underlying racial-related barriers to hepatitis C virus treatment besides socioeconomic status and medical or psychiatric comorbidities.</description><subject>Adult</subject><subject>Continental Population Groups</subject><subject>Female</subject><subject>Hepatitis C, Chronic - ethnology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Morbidity - trends</subject><subject>Observational Study</subject><subject>Population Surveillance - methods</subject><subject>Retrospective Studies</subject><subject>United States - epidemiology</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkd1u1DAQhS0EotvCEyAhX3JByvg_5gKpZIEitaIq7bXlTRxiyMap7W3Vd-Ch8XZLVfCNrTnfnDPyIPSKwCEBrd6dLg_h0WGK6CdoQQSTldCSP0ULACoqpRXfQ_sp_QQgTFH-HO1RRUXNdb1Av89t6-2Ilz7NNvrsXcJ-whfR2bx2U8bnNpdSHyJuhhgm3-JjN9tcyISb9_hosuNtKu_QY4vPwrwZixim6qNNrsNNGELMW1Gxt1IKfFbUYnsXkgeHLyefC_c9b2NeoGe9HZN7eX8foMvPny6a4-rk25evzdFJ1TIhaCW6TinCuJRkxdyqdgykYKTXvVOUCcdWHVMarBQ1hVYRblvbQSeEAC46p9gB-rDznTertevaMlC0o5mjX9t4a4L15l9l8oP5Ea4N1wAKZDF4c28Qw9XGpWzWPrVuHO3kwiYZojTTwGvgBWU7tI0hpej6hxgCZrtHc7o0_--xdL1-POFDz9_FFYDvgJswZhfTr3Fz46IZnB3zcOcnlKYVBSKh_A1UpUIo-wPx_ag4</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Vutien, Philip</creator><creator>Hoang, Joseph</creator><creator>Brooks, Louis</creator><creator>Nguyen, Nghia H.</creator><creator>Nguyen, Mindie H.</creator><general>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160501</creationdate><title>Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States</title><author>Vutien, Philip ; Hoang, Joseph ; Brooks, Louis ; Nguyen, Nghia H. ; Nguyen, Mindie H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3552-5dd77134661b3eb8e306531f9fe7235e3bd3790a65820c714acad0d555045de73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Continental Population Groups</topic><topic>Female</topic><topic>Hepatitis C, Chronic - ethnology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Morbidity - trends</topic><topic>Observational Study</topic><topic>Population Surveillance - methods</topic><topic>Retrospective Studies</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vutien, Philip</creatorcontrib><creatorcontrib>Hoang, Joseph</creatorcontrib><creatorcontrib>Brooks, Louis</creatorcontrib><creatorcontrib>Nguyen, Nghia H.</creatorcontrib><creatorcontrib>Nguyen, Mindie H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vutien, Philip</au><au>Hoang, Joseph</au><au>Brooks, Louis</au><au>Nguyen, Nghia H.</au><au>Nguyen, Mindie H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2016-05-01</date><risdate>2016</risdate><volume>95</volume><issue>22</issue><spage>e3719</spage><epage>e3719</epage><pages>e3719-e3719</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Chronic hepatitis C (CHC) disproportionately affects racial minorities in the United States (US). Although prior studies have reported lower treatment rates in Blacks than in Caucasians, the rates of other minorities remain understudied. We aimed to examine antiviral treatment rates by race and to evaluate the effect of other demographic, medical, and psychiatric factors on treatment rates. We performed a population-based study of adult CHC patients identified via ICD-9CM query from OptumInsight's Data Mart from January 2009 to December 2013. Antiviral treatment was defined by pharmaceutical claims for interferon and/or pegylated-interferon. A total of 73,665 insured patients were included: 51,282 Caucasians, 10,493 Blacks, 8679 Hispanics, and 3211 Asians. Caucasians had the highest treatment rate (10.7%) followed by Blacks (8.8%), Hispanics (8.8%), and Asians (7.9%, P &lt; .001). Hispanics had the highest cirrhosis rates compared with Caucasians, Blacks, and Asians (20.7% vs 18.3%, 17.1%, and 14.3%, respectively). Caucasians were the most likely to have a psychiatric comorbidity (20.1%) and Blacks the most likely to have a medical comorbidity (44%). Asians were the least likely to have a psychiatric (6.4%) or medical comorbidity (26.9%). On multivariate analysis, racial minority was a significant predictor of nontreatment with odds ratios of 0.82 [confidence interval (CI): 0.74-0.90] for Blacks, 0.87 (CI: 0.78-0.96) for Hispanics, and 0.73 (CI: 0.62-0.86) for Asians versus Caucasians. Racial minorities had lower treatment rates than Caucasians. Despite fewer medical and psychiatric comorbidities and higher incomes and educational levels, Asians had the lowest treatment rates. Hispanics also had lower treatment rates than Caucasians despite having higher rates of cirrhosis. Future studies should aim to identify underlying racial-related barriers to hepatitis C virus treatment besides socioeconomic status and medical or psychiatric comorbidities.</abstract><cop>United States</cop><pub>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>27258498</pmid><doi>10.1097/MD.0000000000003719</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2016-05, Vol.95 (22), p.e3719-e3719
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4900706
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; PubMed Central; Alma/SFX Local Collection
subjects Adult
Continental Population Groups
Female
Hepatitis C, Chronic - ethnology
Humans
Male
Middle Aged
Morbidity - trends
Observational Study
Population Surveillance - methods
Retrospective Studies
United States - epidemiology
title Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T17%3A08%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Racial%20Disparities%20in%20Treatment%20Rates%20for%20Chronic%20Hepatitis%20C:%20Analysis%20of%20a%20Population-Based%20Cohort%20of%2073,665%20Patients%20in%20the%20United%20States&rft.jtitle=Medicine%20(Baltimore)&rft.au=Vutien,%20Philip&rft.date=2016-05-01&rft.volume=95&rft.issue=22&rft.spage=e3719&rft.epage=e3719&rft.pages=e3719-e3719&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000003719&rft_dat=%3Cproquest_pubme%3E1793904804%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1793904804&rft_id=info:pmid/27258498&rfr_iscdi=true